ABO blood group in patients with malignant trophoblastic disease.
ABO blood group was analyzed in 70 patients with hydatidiform mole and 53 patients with malignant trophoblastic disease. 319 healthy pregnant women served as controls. The distribution of ABO blood groups in patients with hydatidiform mole did not deviate significantly from the distribution in the controls. There was a slight excess in group AB and a slight deficiency in group O in patients with hydatidiform mole. However, there was a significant decrease in blood group A and a slight excess in groups O, B and AB in patients with malignant trophoblastic disease compared with the distribution in healthy pregnant women. A higher mortality rate was observed in group B in patients with malignant trophoblastic disease. In conclusion, ABO blood group of patients with malignant trophoblastic disease can be an important prognostic factor in the diagnosis and treatment of the trophoblastic disease, if a large number of cases are compiled by many investigators.
D000017:ABO Blood-Group System; D002822:Choriocarcinoma / Q000097:blood; D005260:Female; D006801:Humans; D006828:Hydatidiform Mole / Q000097:blood*; D011247:Pregnancy; D012016:Reference Values; D014328:Trophoblastic Neoplasms / Q000097:blood*; D014594:Uterine Neoplasms / Q000097:blood*
D000017:ABO Blood-Group System